Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Business > Not perfect, but saves lives, AstraZeneca says of COVID-19 vaccine

Not perfect, but saves lives, AstraZeneca says of COVID-19 vaccine

Published by linker 5

Posted on February 11, 2021

3 min read

Last updated: January 21, 2026

AstraZeneca COVID-19 vaccine distribution at a hospital - Global Banking & Finance Review — Image depicting the distribution of the AstraZeneca COVID-19 vaccine, highlighting its significance in the pandemic response. This vaccine is considered vital for global vaccination efforts.

By Pushkala Aripaka and Ludwig Burger

(Reuters) – AstraZeneca’s COVID-19 vaccine is not perfect, but will have a big impact on the pandemic, its chief executive predicted on Thursday, as the drugmaker pledged to double supplies to more than 200 million doses per month by April.

The two-dose shot, developed with Oxford University, has been hailed as a “vaccine for the world” because it is cheaper and easier to distribute than some rivals.

But its rapid approval in Europe and elsewhere has been clouded by doubts over its most effective dosage and interval between doses.

Data at the weekend also showed it was less effective against a fast-spreading South African variant of the virus, and the company has been embroiled in a row with the European Union over supply delays.

“Is it perfect? No it’s not perfect, but it’s great. Who else is making 100 million doses in February?” CEO Pascal Soriot said on a conference call about the vaccine.

“We’re going to save thousands of lives and that’s why we come to work everyday.”

AstraZeneca said it expected much-anticipated data from the U.S. trial of the vaccine before the end of March, and that it was confident the shot offered relatively good protection against severe disease and death for the South African variant. Its disappointing results were against milder cases.

However, after rising to become Britain’s most valuable company last summer, the company has now slipped to sixth, in a move some analysts attribute to doubts over the vaccine.

“In a year or two we will look back and everybody will realise we made a big impact,” Soriot said.

POSTER CHILD

AstraZeneca’s shares were up more than 2% in morning trade, after the company forecast a pick up in earnings growth this year on strong demand for its cancer and other new therapies.

It has pledged not to make any money from its COVID-19 vaccine during the pandemic.

The company said it expected 2021 revenues to rise by a low teens percentage and core earnings of $4.75 to $5.00 per share, as it beat expectations for fourth-quarter sales.

The earnings guidance equates to 18-24% growth, after 15% in 2020, but was a little lower than the $5.10 per share analysts were expecting, as the company flagged more spending this year.

The COVID-19 vaccine is not included in the guidance and the company said its sales would be reported separately from the first quarter of 2021.

While public interest is focused on the vaccine, AstraZeneca’s core business of diabetes, heart, kidney, and cancer medicines has been steadily growing, helping the company to turn around years of decline.

Rounding off its third consecutive year of product sales growth, sales for the three months to December surpassed a company-compiled consensus, while core profit of $1.07 per share was in line with expectations.

Cancer drugs sales, AstraZeneca’s biggest field, jumped 28% in the quarter, led by its top-selling lung cancer drug Tagrisso.

“The company is arguably the poster child for big pharma turnarounds,” said Third Bridge senior analyst Sebastian Skeet.

Graphic: AstraZeneca shares vs rivals, https://fingfx.thomsonreuters.com/gfx/mkt/yzdvxwdwwpx/AZ%20chart.PNG

(Reporting by Pushkala Aripaka in Bengaluru and Ludwig Burger in Frankfurt. Editing by Shounak Dasgupta and Mark Potter)